In summary, reduced levels of CREMα can suppress the production of IL-17 and reduce the pool of pathogenic DN T cells, which suggests its potential as a disease biomarker and therapeutic target in SLE. The gene discussed is IL17A; the disease is systemic lupus erythematosus.